Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Sunitinib as a Second-line Treatment for Patients With Recurrent Small Cell Lung Cancer.

NCT00620347 is registered in ClinicalTrials.gov with National Cancer Center, Korea as lead sponsor.

NCT NCT00620347
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00620347 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Sunitinib as a Second-line Treatment for Patients With Recurrent Small Cell Lung Cancer.
Lead sponsor
National Cancer Center, Korea
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2008
Completion date
September 30, 2012
Enrollment
25 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer